Sign In
Buy GLP
$48.46
-0.170 (-0.350%)
At Close: Jul 29, 2026
3 Fantastic Growth Opportunities for Eli Lilly That Go Beyond GLP-1 Drugs
01:58pm, Sunday, 09'th Nov 2025
Eli Lilly has been investing in radiopharmaceuticals, which can help revolutionize cancer care in the future. Its early Alzheimer's drug, Kisunla, has blockbuster potential, and if efforts at early de
Eli Lilly's Breakout Is Here - Growing GLP-1 Market Share
09:15am, Saturday, 08'th Nov 2025
LLY's Mounjaro and Zepbound deliver accelerated weight loss rates compared to NVO's Wegovy, which perhaps explains the former's triple digits GLP-1 revenue growth on a YoY basis. This is on top of LLY
Why Omada Health is finally prescribing Ozempic as TrumpRx slashes GLP-1 weight-loss drug costs
12:47pm, Friday, 07'th Nov 2025
Trump said Thursday that TrumpRx would offer discounts on GLP-1 drugs for weight loss. A few hours later, Omada Health said it will prescribe the drugs starting in 2026.
Eli Lilly, Novo Nordisk's Historic GLP-1 Pricing Deals - What Investors Need To Know
11:49am, Friday, 07'th Nov 2025
Novo Nordisk A/S and Eli Lilly and Company have agreed to slash US prices for Ozempic, Wegovy, Mounjaro, and Zepbound, expanding Medicare/Medicaid access. NVO's stock has dropped sharply in 2025, but
Global Partners LP Common Units (GLP) Q3 2025 Earnings Call Transcript
11:16am, Friday, 07'th Nov 2025
Global Partners LP Common Units ( GLP ) Q3 2025 Earnings Call November 7, 2025 10:00 AM EST Company Participants Sean Geary - Chief Legal Officer & Secretary Eric Slifka - President, CEO & Vice Chairm
Global Partners Reports Third-Quarter 2025 Financial Results
08:00am, Friday, 07'th Nov 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global” or the “Partnership”) today reported financial results for the third quarter ended September 30, 2025. CEO Commentary
Medicare to Cover GLP-1 Drugs for as Little as $50 a Month
05:04pm, Thursday, 06'th Nov 2025
Seniors could soon pay just $50 a month for Ozempic and other drugs used for weight loss under a new Trump plan to cut prescription costs.
Omada Health Announces GLP-1 Prescribing Capability to Support Growing Member Population
04:10pm, Thursday, 06'th Nov 2025
SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit health care provider, today announced the planned launch of its prescribing capability. A
Omada Health Reports Third Quarter 2025 Results
04:10pm, Thursday, 06'th Nov 2025
Revenue of $ 68 million, up 49% ; 53% Member Growth Significant Reduction in Net Loss and First Quarter of Positive Adjusted EBITDA Announces New GLP-1 Prescribing Offering SAN FRANCISCO, Nov. 06, 202
Startup Omada Health to start prescribing GLP-1s, other obesity medications as membership grows
04:05pm, Thursday, 06'th Nov 2025
Virtual care company Omada Health said it will start prescribing GLP-1s and other obesity drugs and help patients manage those medications. The announcement expands the offerings under the company's w
Eli Lilly and Novo Nordisk lower GLP-1 drug costs in new deal with Trump.
03:30pm, Thursday, 06'th Nov 2025
About Yahoo Finance: Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage
Novo Nordisk announces agreement with the U.S. Administration to bring GLP-1s to more Americans at a lower cost
01:01pm, Thursday, 06'th Nov 2025
Novo Nordisk has agreed with the U.S.
2 Reasons I'm Keeping My Eye on Eli Lilly Stock Right Now
06:09pm, Wednesday, 05'th Nov 2025
Eli Lilly is dominating the large and rapidly growing incretin analog market in the U.S. with its GLP-1 drug, tirzepatide. Its investigational oral GLP-1 drug, orforglipron, could significantly expand
Novo Nordisk Is Seeing Slowing Demand for GLP-1s Wegovy and Ozempic
12:00pm, Wednesday, 05'th Nov 2025
U.S.-listed shares of Novo Nordisk (NVO) fell after the drugmaker scaled back its outlook, citing disappointing demand for its GLP-1 weight loss and diabetes drugs as competition in the sector increas
Novo Nordisk Slides as GLP-1 Fatigue and Pricing Risks Cloud 2025 Outlook
11:54am, Wednesday, 05'th Nov 2025
Shares of Novo Nordisk (NVO) slipped about 1% on Wednesday morning after the company issued a cautious outlook, even though third-quarter revenue exceeded estim
